Names: Cobicistat, Tybost
Approved dosage: Cobicistat is a boosting agent available as a 150mg tablet (Tybost) for boosting of darunavir or atazanavir, or incorporated in several products:
- Evotaz (atazanavir/cobicistat)
- Rezolsta (darunavir/cobicistat)
- Stribild (elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine)
- Genvoya (elvitegravir/cobicistat/tenofovir alafenamide/emtricitabine
- Symtuza (darunavir/cobicistat/tenofovir alafenamide/emtricitabine).
Common side effects: Raised blood sugar, increased appetite, difficulty in sleeping, drowsiness, abnormal dreams, headache, dizziness, altered sense of taste, nausea, diarrhoea, abdominal pain, bloating, flatulence, dry mouth, jaundice, rash, and tiredness.
Rare side effects: Kidney stones
Key drug interactions: As a boosting agent, cobicistat can also interact with other medicines. See the drug interaction information for the agents listed above for specific drug interaction information.
Cobicistat should not be used with alfusozin, ranolazine, dronedarone, carbamazepine, phenobarbital, phenytoin, rifampicin, lurasidone pimozide, dihydroergotamine, ergotamine, cisapride, lovastatin, simvastatin, triazolam or oral midazolam.